Interim Report January – March 2018

Continued progress of the project portfolio  January - March 2018 Net sales for the period amounted to SEK 52.3 million (26.2)  Operating profit amounted to SEK ...

Full Year Report January – December 2017

Successful IPO and continued positive result for BioArctic. October – December 2017. Net sales for the period amounted to SEK 51.0 million (94.4). Operating profit amounted ...

Interim Report January – September 2017

BioArctic listed on Nasdaq Stockholm Mid Cap. July - September 2017- Net sales for the period amounted to SEK 31.5 million (1.2). Operating profit amounted to SEK ...

Stabilization notice

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

BioArctic AB intends to list on Nasdaq Stockholm

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH ...

Drug Candidate Receives Orphan Drug Designation

The text below is a translation of a Swedish press release. BioArctic Neuroscience develops treatments to help victims of spinal cord injury. The European Medicines Agency ...

Proud partner of: